{"transactions":[{"id":3698699,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-01-10T22:25:39.000Z","date":"2019-01-10","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":50000,"derivative":{"exercise_price":0.66,"expiration_date":"2024-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-000988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319000988/doc4.xml","form_type":"4"}},{"id":3698698,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-01-10T22:25:39.000Z","date":"2019-01-10","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.66,"expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-000988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319000988/doc4.xml","form_type":"4"}},{"id":3698697,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-01-10T22:25:39.000Z","date":"2019-01-10","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":100000,"derivative":{"exercise_price":0.64,"expiration_date":"2024-05-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-000988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319000988/doc4.xml","form_type":"4"}},{"id":3698696,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-01-10T22:25:39.000Z","date":"2019-01-10","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the \"old\" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.64,"expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-000988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319000988/doc4.xml","form_type":"4"}},{"id":3760318,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":false,"nature":"By Caracciolo Group LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":200000,"derivative":{"exercise_price":0.75,"exercise_date":"2017-11-08","expiration_date":"2022-11-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760317,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":333333,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":333333,"derivative":{"exercise_price":0.75,"exercise_date":"2017-06-19","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760316,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":333333,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":333333,"derivative":{"exercise_price":0.75,"exercise_date":"2017-05-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760315,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":1333334,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":1333334,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":1333334},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760314,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":950000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest in equal monthly installments over the two-year period commencing on July 8, 2018."}],"balance_after":950000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":950000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760313,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760312,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":128530,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":128530,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":128530},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760311,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options (including predecessor options) vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":450000,"derivative":{"exercise_price":0.76,"expiration_date":"2027-02-12","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760310,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":550000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options (including predecessor options) vest in equal monthly installments over the two-year period commencing on March 12, 2017."}],"balance_after":550000,"derivative":{"exercise_price":0.76,"expiration_date":"2027-02-12","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760309,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760308,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":250000,"derivative":{"exercise_price":0.97,"exercise_date":"2015-06-11","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760307,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760306,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":25000,"derivative":{"exercise_price":1.55,"exercise_date":"2013-06-01","expiration_date":"2022-06-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760305,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":11543,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":11543,"derivative":{"exercise_price":2.9,"exercise_date":"2013-05-21","expiration_date":"2022-05-21","underlying":"Common Stock","underlying_shares":11543},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760304,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.66,"exercise_date":"2015-06-01","expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760303,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":100000,"derivative":{"exercise_price":0.64,"exercise_date":"2014-05-29","expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760302,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":62136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":62136,"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760301,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":26000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760300,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":false,"nature":"By Caracciolo Group LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3760299,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:00:19.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":2093972,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":2093972,"source":{"system":"sec-edgar","filing":"0000899243-18-029254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029254/doc4.xml","form_type":"4"}},{"id":3762658,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":false,"nature":"By Caracciolo Group LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2017-11-08","expiration_date":"2022-11-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762657,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":666666,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":666666},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762656,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1333334,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":1333334},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762655,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":950000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest in equal monthly installments over the two-year period commencing on July 8, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":950000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762654,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762653,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":128530,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":128530},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762652,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":0,"derivative":{"exercise_price":0.76,"expiration_date":"2027-02-12","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762651,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":550000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in equal monthly installments over the two-year period commencing on March 12, 2017."}],"balance_after":0,"derivative":{"exercise_price":0.76,"expiration_date":"2027-02-12","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762650,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762649,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.97,"exercise_date":"2015-06-11","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762648,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762647,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.55,"exercise_date":"2013-06-01","expiration_date":"2022-06-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762646,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":11543,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":2.9,"exercise_date":"2013-05-21","expiration_date":"2022-05-21","underlying":"Common Stock","underlying_shares":11543},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762645,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.66,"exercise_date":"2015-06-01","expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762644,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.64,"exercise_date":"2014-05-29","expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762643,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":62136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762642,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":26000,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762641,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":false,"nature":"By Caracciolo Group LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762640,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:26:50.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":2093972,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029186/doc4.xml","form_type":"4"}},{"id":3762613,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants","published_at":"2018-11-16T22:30:34.000Z","date":"2017-06-19","kind":"disposition_to_issuer","acquired":false,"shares":333333,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This report is being filed to correct certain inadvertent errors, to report (i) the warrant issued May 31, 2017 as disposed of (and not acquired) in the transaction, in Column 5, and (ii) the number of such derivative securities beneficially owned following the transaction as zero (and not 333,333), in Column 9."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As part of a private offering to accredited investors, on May 31, 2017, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note, with an exercise price of $1.35 per share. Effective June 19, 2017, the issuer amended the terms of the offering to increase the warrant coverage from 25% to 50% and to decrease the warrant exercise price from $1.35 to $1.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This report is being filed to correct certain inadvertent errors, to report (i) the warrant issued May 31, 2017 as disposed of (and not acquired) in the transaction, in Column 5, and (ii) the number of such derivative securities beneficially owned following the transaction as zero (and not 333,333), in Column 9."}],"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2017-05-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0000899243-18-029164","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029164/doc4a.xml","form_type":"4/A","original_submission_date":"2017-06-21"}},{"id":3822890,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-09-07T22:25:17.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":666666,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the \"old\" warrant and the acquisition of a new one."}],"balance_after":666666,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":666666},"source":{"system":"sec-edgar","filing":"0000899243-18-024032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318024032/doc4.xml","form_type":"4"}},{"id":3822889,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-09-07T22:25:17.000Z","date":"2018-01-31","kind":"disposition_to_issuer","acquired":false,"shares":666666,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the \"old\" warrant and the acquisition of a new one."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2017-05-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":666666},"source":{"system":"sec-edgar","filing":"0000899243-18-024032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318024032/doc4.xml","form_type":"4"}},{"id":3897813,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2018-06-12T21:58:12.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":950000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over the next two years, commencing on the first month following the grant date."}],"balance_after":950000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":950000},"source":{"system":"sec-edgar","filing":"0000899243-18-016233","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318016233/doc4.xml","form_type":"4"}},{"id":4053919,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:00:36.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-004433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004433/doc4.xml","form_type":"4"}},{"id":4053918,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:00:36.000Z","date":"2018-02-15","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.8,"expiration_date":"2018-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-004433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004433/doc4.xml","form_type":"4"}},{"id":4069752,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-10T01:00:00.000Z","date":"2018-02-07","kind":"grant","acquired":true,"shares":128530,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model."}],"balance_after":128530,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":128530},"source":{"system":"sec-edgar","filing":"0000899243-18-003451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318003451/doc4.xml","form_type":"4"}},{"id":4080904,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2018-02-03T01:18:31.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":1333334,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants."}],"balance_after":1333334,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":1333334},"source":{"system":"sec-edgar","filing":"0000899243-18-002767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318002767/doc4.xml","form_type":"4"}},{"id":4080903,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-02-03T01:18:31.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":2093972,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants."}],"balance_after":2093972,"source":{"system":"sec-edgar","filing":"0000899243-18-002767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318002767/doc4.xml","form_type":"4"}},{"id":4169740,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2017-11-08T21:30:38.000Z","date":"2017-11-08","kind":"grant","acquired":false,"shares":200000,"ownership":{"direct":false,"nature":"By limited liability company"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a private offering to accredited investors, at a combined price of $0.50 per share of common stock and a warrant covering 100% of the number of shares of common stock purchased."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":200000,"derivative":{"exercise_price":0.75,"exercise_date":"2017-11-08","expiration_date":"2022-11-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-17-025602","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317025602/doc4.xml","form_type":"4"}},{"id":4169739,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2017-11-08T21:30:38.000Z","date":"2017-11-08","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":false,"nature":"By limited liability company"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a private offering to accredited investors, at a combined price of $0.50 per share of common stock and a warrant covering 100% of the number of shares of common stock purchased."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000899243-17-025602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317025602/doc4.xml","form_type":"4"}},{"id":4275848,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants","published_at":"2017-06-22T01:30:50.000Z","date":"2017-06-19","kind":"disposition_to_issuer","acquired":true,"shares":333333,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As part of a private offering to accredited investors, on May 31, 2017, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note, with an exercise price of $1.35 per share.  Effective June 19, 2017, the issuer amended the terms of the offering to increase the warrant coverage from 25% to 50% and to decrease the warrant exercise price from $1.35 to $1.00.  As reflected in this Form 4, the issuer applied such amended terms retroactively to all warrants previously purchased in the offering."}],"balance_after":333333,"derivative":{"exercise_price":1.35,"exercise_date":"2017-05-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0000899243-17-016914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317016914/doc4.xml","form_type":"4"}},{"id":4275847,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants","published_at":"2017-06-22T01:30:50.000Z","date":"2017-06-19","kind":"grant","acquired":true,"shares":666666,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As part of a private offering to accredited investors, on May 31, 2017, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note, with an exercise price of $1.35 per share.  Effective June 19, 2017, the issuer amended the terms of the offering to increase the warrant coverage from 25% to 50% and to decrease the warrant exercise price from $1.35 to $1.00.  As reflected in this Form 4, the issuer applied such amended terms retroactively to all warrants previously purchased in the offering."}],"balance_after":666666,"derivative":{"exercise_price":1,"exercise_date":"2017-05-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":666666},"source":{"system":"sec-edgar","filing":"0000899243-17-016914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317016914/doc4.xml","form_type":"4"}},{"id":4297430,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants","published_at":"2017-06-02T22:03:23.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":333333,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note."}],"balance_after":333333,"derivative":{"exercise_price":1.35,"exercise_date":"2017-05-31","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0000899243-17-015190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015190/doc4.xml","form_type":"4"}},{"id":4297429,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Convertible Promissory Note","published_at":"2017-06-02T22:03:23.000Z","date":"2017-05-31","kind":"grant","acquired":true,"reported_value":1000000,"ownership":{"direct":false,"nature":"By Caracciolo Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Does not include additional shares issuable upon conversion of accrued interest."}],"derivative":{"exercise_price":0.75,"exercise_date":"2017-05-31","expiration_date":"2018-01-31","underlying":"Common Stock","underlying_shares":1333333},"source":{"system":"sec-edgar","filing":"0000899243-17-015190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015190/doc4.xml","form_type":"4"}},{"id":4456357,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2017-02-13T21:42:45.000Z","date":"2017-02-12","kind":"grant","acquired":true,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in equal monthly installments over the next two years, commencing on the first month following the grant date."}],"balance_after":550000,"derivative":{"exercise_price":0.76,"expiration_date":"2027-02-12","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0000899243-17-003796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317003796/doc4.xml","form_type":"4"}},{"id":4456356,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"Caracciolo Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Options (right to buy)","published_at":"2017-02-13T21:42:45.000Z","date":"2017-02-12","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval of the increase in the number of shares authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, at the next annual meeting, the options will vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":450000,"derivative":{"exercise_price":0.76,"expiration_date":"2027-02-12","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-17-003796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317003796/doc4.xml","form_type":"4"}},{"id":588376,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2007-01-24T21:54:03.000Z","date":"2007-01-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012."}],"balance_after":40000,"derivative":{"exercise_price":65.58,"expiration_date":"2017-01-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179110-07-001863","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911007001863/edgar.xml","form_type":"4"}},{"id":608459,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-qualified stock option (right to buy)","published_at":"2006-05-11T19:52:45.000Z","date":"2006-05-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest 20% on May 9, 2007, the first anniversary date of the grant.  The balance will vest every three months over the next four years and will be fully vested by May 9, 2011."}],"balance_after":40000,"derivative":{"exercise_price":56.52,"expiration_date":"2016-05-09","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179110-06-010556","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911006010556/edgar.xml","form_type":"4"}},{"id":621586,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-qualified Stock Option (right to buy)","published_at":"2006-01-28T00:57:04.000Z","date":"2006-01-25","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options have a five year vesting schedule. 20% of the options will vest on January 25, 2007, the first anniversary date of the grant.  The balance will vest 5% every three months thereafter until fully vested on January 25, 2011."}],"balance_after":65000,"derivative":{"exercise_price":58.01,"expiration_date":"2016-01-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001179110-06-002225","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911006002225/edgar.xml","form_type":"4"}},{"id":627707,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":false,"shares":36602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 20% on the first anniversary date of the grant and the balance vested quarterly for the next 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":17.885,"exercise_date":"2004-01-29","expiration_date":"2013-01-28","underlying":"Common Stock","underlying_shares":36602},"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627706,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 20% on the first anniversary date of the grant and the balance vested quarterly for the next 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":15.56,"exercise_date":"2003-05-01","expiration_date":"2012-04-30","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627705,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 20% on the first anniversary date of the grant and the balance vested quarterly for the next 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.4375,"exercise_date":"2003-01-30","expiration_date":"2012-01-29","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627704,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 20% on the first anniversary date of the grant and the balance vested quarterly for the next 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":17.1625,"exercise_date":"2002-10-25","expiration_date":"2011-10-24","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627703,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":false,"shares":2512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 20% on the first anniversary date of the grant and the balance vested quarterly for the next 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.3985,"exercise_date":"2002-01-18","expiration_date":"2011-01-17","underlying":"Common Stock","underlying_shares":2512},"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627702,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":false,"shares":7776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 20% on the first anniversary date of the grant and the balance vested quarterly for the next 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.3985,"exercise_date":"2002-01-18","expiration_date":"2011-01-17","underlying":"Common Stock","underlying_shares":7776},"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627701,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":42919,"price":54,"value":2317626.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627700,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":675,"price":54.01,"value":36456.75,"ownership":{"direct":true},"balance_after":42919,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627699,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":3652,"price":54.02,"value":197281.04,"ownership":{"direct":true},"balance_after":43594,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627698,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":1007,"price":54.03,"value":54408.21,"ownership":{"direct":true},"balance_after":47246,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627697,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":3568,"price":54.05,"value":192850.4,"ownership":{"direct":true},"balance_after":48252,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627696,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":2648,"price":54.06,"value":143150.88,"ownership":{"direct":true},"balance_after":51821,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627695,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":2540,"price":54.07,"value":137337.8,"ownership":{"direct":true},"balance_after":54469,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627694,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":5423,"price":54.08,"value":293275.84,"ownership":{"direct":true},"balance_after":57009,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627693,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":400,"price":54.04,"value":21616.0,"ownership":{"direct":true},"balance_after":62432,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627692,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":13346,"price":54.09,"value":721885.14,"ownership":{"direct":true},"balance_after":62832,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627691,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":2055,"price":54.1,"value":111175.5,"ownership":{"direct":true},"balance_after":76178,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627690,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":6769,"price":54.11,"value":366270.59,"ownership":{"direct":true},"balance_after":78233,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627689,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":4616,"price":54.13,"value":249864.08,"ownership":{"direct":true},"balance_after":85002,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627688,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":14438,"price":54.15,"value":781817.7,"ownership":{"direct":true},"balance_after":89618,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627687,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":1042,"price":54.12,"value":56393.04,"ownership":{"direct":true},"balance_after":104056,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627686,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":6018,"price":54.14,"value":325814.52,"ownership":{"direct":true},"balance_after":105098,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627685,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":4173,"price":54.16,"value":226009.68,"ownership":{"direct":true},"balance_after":111116,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627684,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":3572,"price":54.17,"value":193495.24,"ownership":{"direct":true},"balance_after":115289,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627683,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":8128,"price":54.18,"value":440375.04,"ownership":{"direct":true},"balance_after":118861,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627682,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":900,"price":54.19,"value":48771.0,"ownership":{"direct":true},"balance_after":126989,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627681,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"sale","acquired":false,"shares":3001,"price":54.2,"value":162654.2,"ownership":{"direct":true},"balance_after":127889,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627680,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":true,"shares":36602,"price":17.885,"value":654626.77,"ownership":{"direct":true},"balance_after":130890,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627679,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":true,"shares":18000,"price":15.56,"value":280080.0,"ownership":{"direct":true},"balance_after":94288,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627678,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":true,"shares":39000,"price":16.4375,"value":641062.5,"ownership":{"direct":true},"balance_after":76288,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627677,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":true,"shares":27000,"price":17.1625,"value":463387.5,"ownership":{"direct":true},"balance_after":37288,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627676,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":true,"shares":2512,"price":7.3985,"value":18585.032,"ownership":{"direct":true},"balance_after":10288,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":627675,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Manufacturing"}}],"security":"Common Stock","published_at":"2005-11-24T01:13:08.000Z","date":"2005-11-22","kind":"exercise","acquired":true,"shares":7776,"price":7.3985,"value":57530.736,"ownership":{"direct":true},"balance_after":7776,"source":{"system":"sec-edgar","filing":"0001179110-05-021772","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005021772/edgar.xml","form_type":"4"}},{"id":635455,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2005-07-29T23:29:09.000Z","date":"2005-07-27","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest 20% on July 27, 2006, the first anniversary date of the grant. The remaining balance will vest quarterly over the next four years."}],"balance_after":30000,"derivative":{"exercise_price":43.97,"expiration_date":"2015-07-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-05-015032","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005015032/edgar.xml","form_type":"4"}},{"id":639991,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2005-05-12T22:21:04.000Z","date":"2005-05-10","kind":"sale","acquired":false,"shares":1800,"price":38.88,"value":69984.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-05-009719","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005009719/edgar.xml","form_type":"4"}},{"id":639990,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2005-05-12T22:21:04.000Z","date":"2005-05-10","kind":"sale","acquired":false,"shares":518,"price":38.8701,"value":20134.7118,"ownership":{"direct":true},"balance_after":1800,"source":{"system":"sec-edgar","filing":"0001179110-05-009719","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005009719/edgar.xml","form_type":"4"}},{"id":639989,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":17294,"kind":"person","name":"Caracciolo Anthony","position":1,"cik":"0001258929","reported_name":"CARACCIOLO ANTHONY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP"}}],"security":"Common Stock","published_at":"2005-05-12T22:21:04.000Z","date":"2005-05-10","kind":"sale","acquired":false,"shares":1000,"price":38.87,"value":38870.0,"ownership":{"direct":true},"balance_after":2318,"source":{"system":"sec-edgar","filing":"0001179110-05-009719","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911005009719/edgar.xml","form_type":"4"}}],"next_cursor":"2005-05-12T22:21:04.000000Z,639989"}